<DOC>
	<DOCNO>NCT02998437</DOCNO>
	<brief_summary>This study evaluate pharmacokinetic drug interaction Ilaprazole , Clarithromycin , Amoxicillin .</brief_summary>
	<brief_title>Study Evaluate Pharmacokinetic Drug Interactions Safety Clarithromycin , Amoxicillin Ilaprazole</brief_title>
	<detailed_description>This study evaluate pharmacokinetic drug interaction safety Ilaprazole , Clarithromycin , Amoxicillin .</detailed_description>
	<mesh_term>Clarithromycin</mesh_term>
	<mesh_term>Amoxicillin</mesh_term>
	<criteria>1 . Healthy male adult age ≥19 year &lt; 50 year screen 2 . Body mass index ≥18.5 &lt; 25 Body mass index ( kg/m2 ) = body weight ( kg ) / [ height ( ) ] 2 3 . Men sexual relationship woman child bear potential must give consent use contraceptive measure ( condom , spermicide , menstrual cycle control ) avoid sperm donation study 28 day follow last dose IMP ( contraceptive measure require male subject female partner infertile ) . 4 . Those voluntarily decide participate study give write consent comply requirement receive sufficient explanation fully understanding study . 1 . Hypersensitivity history clinically significant hypersensitivity active ingredient excipients ( particular , Yellow No . 4 ( Tartrazine ) ; Yellow No . 5 ( Sunset Yellow FCF ) ; macrolide antibiotic Clarithromycin erythromycin ; Penicillins ) 2 . History QT prolongation ventricular arrhythmia ( include Torsadedes de pointes ) 3 . Clinically significant , current past disorder hepatobiliary ( severe hepatic impairment , etc . ) , renal ( severe renal impairment , etc . ) , nervous , immune , respiratory , endocrine , blood•tumor , cardiovascular ( heart failure , etc . ) , psychiatric system 4 . History gastrointestinal disorder ( Crohn 's disease , ulcer , etc . ) operation ( exclude simple appendectomy herniotomy ) may affect drug absorption 5 . Administration IMP study ( include biological comparability test ) within 3 month first dose IMP . 6 . Whole blood donation within 60 day , apheresis donation within 30 day first dose IMP . 7 . Constant caffeine intake ( &gt; 5 cup coffee/day , &gt; 1250 cc tea/day , &gt; 1250 cc cola/day ) , constant smoking ( 10 cigarettes/day ) constant alcohol drinking ( 210 g/week ) inability refrain alcohol consumption 2 day first dose IMP end PK assessment . 8 . Consumption grapefruitcontaining food within 7 day first dose IMP 9 . History drug abuse within 1 year screening , positive response urine drug misuse/abuse screen test 10 . Use medicinal product expect may affect metabolism IMP ; St. John 's wort ; relevant preparation within 30 day IMP administration 11 . Use follow medicinal product within give time period exclude local preparation , significant systemic absorption , hormonal contraceptive Prescription drug within 14 day first dose IMP OTC include health supplement vitamin within 7 day first dose IMP Medicinal product via depot injection implantation within 30 day first dose IMP ( exclude contraceptive ) Drug metabolize enzyme inducer inhibitor barbiturate within 30 day first dose IMP 12 . Stable vital sign measure sit position screening : systolic blood pressure &gt; 150 mmHg &lt; 90 mmHg , diastolic blood pressure &gt; 100 mmHg &lt; 50 mmHg , pulse rate &gt; 110 bpm &lt; 40 bpm 13 . Following finding screen Blood total bilirubin &gt; 1.5 x upper limit normal Blood AST ( SGOT ) , ALT ( SGPT ) &gt; 1.25 x upper limit normal MDRDestimated eGFR &lt; 60 mL/min/1.73m2 eGFR ( estimate glomerular filtration rate ) ( mL/min/1.73m2 ) = 175 x [ serum creatinine ( mg/dL ) ] 1.154 x [ age ( year ) ] 0.203 Positive serum test ( hepatitis B , hepatitis C , HIV , syphilis ) 14 . Those consider ineligible investigator due screen result reason .</criteria>
	<gender>Male</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>